Compounds > l 30
Page last updated: 2024-11-06

l 30

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 30: a sodium channel blocker; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID88832
CHEMBL ID10321
SCHEMBL ID18485526
MeSH IDM0243416

Synonyms (11)

Synonym
l 30
CHEMBL10321
21236-52-2
3-(diethylamino)-n-(2,6-dimethylphenyl)propanamide
3-(diethylamino)-2',6'-propionoxylidide
2',6'-propionoxylidide, 3-(diethylamino)-
AKOS028302367
SCHEMBL18485526
propanamide, 3-(diethylamino)-n-(2,6-dimethylphe
DTXSID90877900
STARBLD0004663
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID317685Anesthetic activity in rat at 4.0 uMol/site assessed as duration of full recovery of sensory block2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Synthesis and antispasmodic activity of lidocaine derivatives endowed with reduced local anesthetic action.
AID114641Compound was evaluated for ataxia in mice1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
New antiarrhythmic agents. 6. Quantitative structure-activity relationships of aminoxylidides.
AID1130840Antiarrhythmic activity in left anterior descending coronary artery ligated myocardial infarction model of dog assessed as mean arterial blood pressure at 0.5 mg/kg/min, iv1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID317683Anesthetic activity in rat at 1.0 uMol/site assessed as duration of full recovery of sensory block2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Synthesis and antispasmodic activity of lidocaine derivatives endowed with reduced local anesthetic action.
AID25320Dissociation constant (pKa)1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
New antiarrhythmic agents. 6. Quantitative structure-activity relationships of aminoxylidides.
AID1130830Toxicity in mouse assessed as ataxia at 100 mg/kg, sc measured up to 20 mins1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID1130836Antiarrhythmic activity in sc dosed mouse assessed as protection against chloroform-induced fibrillation1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID114025Effective dose of compound that evoked CNS toxicity in mice in the form of ataxia1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
New antiarrhythmic agents. 7. 2,3-Diaminopropionanilides.
AID317684Anesthetic activity in rat at 2.0 uMol/site assessed as duration of full recovery of sensory block2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Synthesis and antispasmodic activity of lidocaine derivatives endowed with reduced local anesthetic action.
AID1130833Toxicity in mouse assessed as mortality at 100 mg/kg, sc measured up to 20 mins1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID235211Therapeutic index is the ratio of ED50 (ataxia) to ED50 (protection) in mice1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
New antiarrhythmic agents. 6. Quantitative structure-activity relationships of aminoxylidides.
AID1130848Toxicity in iv dosed left anterior descending coronary artery ligated myocardial infarction model of dog at 0.25 mmol/kg, iv1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID1130844Toxicity in iv dosed left anterior descending coronary artery ligated myocardial infarction model of dog assessed as dose required to cause convulsion1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID1130839Antiarrhythmic activity in left anterior descending coronary artery ligated myocardial infarction model of dog assessed as clearing value of ventricular rate at 0.5 mg/kg/min, iv1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID23494Partition coefficient (logP)1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
New antiarrhythmic agents. 6. Quantitative structure-activity relationships of aminoxylidides.
AID1130832Toxicity in mouse assessed as loss of righting reflex at 100 mg/kg, sc measured up to 20 mins1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID1130841Antiarrhythmic activity in iv dosed left anterior descending coronary artery ligated myocardial infarction model of dog assessed as dose required for reduction of ectopic beats to <= 5%1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID23097Compound was evaluated for -Log [fraction ionized x ED50 (protection)]1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
New antiarrhythmic agents. 6. Quantitative structure-activity relationships of aminoxylidides.
AID174603Anesthetic activity of compound (1.25%) was evaluated by duration of sciatic nerve block; Required days for complete recovery of normal motor function.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
New antiarrhythmic agents. 7. 2,3-Diaminopropionanilides.
AID114027Effective dose of compound that protects mice against chloroform induced tachycardia1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
New antiarrhythmic agents. 7. 2,3-Diaminopropionanilides.
AID317682Anesthetic activity in rat at 0.5 uMol/site assessed as duration of full recovery of sensory block2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Synthesis and antispasmodic activity of lidocaine derivatives endowed with reduced local anesthetic action.
AID1130846Cardiovascular toxicity in iv dosed left anterior descending coronary artery ligated myocardial infarction model of dog1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID174596Anesthetic activity of compound (0.25%) was evaluated by duration of sciatic nerve block1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
New antiarrhythmic agents. 7. 2,3-Diaminopropionanilides.
AID174599Anesthetic activity of compound (1.0%) was evaluated by duration of sciatic nerve block1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
New antiarrhythmic agents. 7. 2,3-Diaminopropionanilides.
AID1130838Antiarrhythmic activity in left anterior descending coronary artery ligated myocardial infarction model of dog assessed as clearing value of ventricular ectopic beats at 0.5 mg/kg/min, iv1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID1130847Toxicity in iv dosed left anterior descending coronary artery ligated myocardial infarction model of dog at 0.20 mmol/kg, iv1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID1130837Ratio of lidocaine ED50 to compound ED50 for antiarrhythmic activity sc dosed mouse assessed as protection against chloroform-induced fibrillation1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 3. Primary beta-amino anilides.
AID174598Anesthetic activity of compound (0.5%) was evaluated by duration of sciatic nerve block1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
New antiarrhythmic agents. 7. 2,3-Diaminopropionanilides.
AID114662Compound was evaluated for protection against tachycardia in mice1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
New antiarrhythmic agents. 6. Quantitative structure-activity relationships of aminoxylidides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.52 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index110.26 (26.88)
Search Engine Supply Index2.23 (0.95)

This Compound (62.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lidocaine
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.		3.2160benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
sulfanilamide
[no description available]		1.9210substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
etidocaine
Etidocaine: A local anesthetic with rapid onset and long action, similar to BUPIVACAINE.. etidocaine : An amino acid amide in which 2-[ethyl(propyl)amino]butanoic acid and 2,6-dimethylaniline have combined to form the amide bond. Used as a local anaesthetic (amide caine), it has rapid onset and long action properties, similar to bupivacaine, and is given by injection during surgical procedures and during labour and delivery.		1.9610amino acid amidelocal anaesthetic
tocainide
Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.		2.6530monocarboxylic acid amideanti-arrhythmia drug;
local anaesthetic;
sodium channel blocker
glycinexylidide
glycinexylidide: dealkylated metabolite of lidocaine; structure; RN given refers to parent cpd with dimethylphenyl moiety in positions 2,6. glycinexylidide : A amino acid amide with 2,6-dimethylaniline and glycine components; an active metabolite of lidocaine, formed by oxidative deethylation. Used as an indicator of hepatic function.		1.9610amino acid amidedrug metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Auricular Fibrillation
[description not available]		01.9510
Atrial Fibrillation
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.		01.9510